Business Wire

Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries

MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the company has enrolled the first patients in a Phase ...
News Medical

Study uses advances in medical imaging to visualize white matter pathways in fetuses

Researchers from the £12 million Developing Human Connectome Project have used the dramatic advances in medical imaging the project has provided to visualize and study white matter pathways, the ...
BioTechniques

Visualize the future of precision medicine with Bio-Techne’s multiomics platform: CRC case study

Bio-Techne’s multiomics platform provides a comprehensive view of disease by combining genomic data with data from other modalities, including transcriptomics, epigenomics, and proteomics. This ...
Business Wire

Vergent Bioscience Presents Phase 2B VISUALIZE Results Demonstrating Abenacianine for Injection (VGT-309) with Intraoperative Molecular Imaging Improved Tumor Visualization ...

MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor targeted imaging agents, announced new data being presented at the 2025 American Society of ...